Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.66 +3.7%	$3.52	$2.45 ▼ $4.14	$290.46M	0.25	387,690 shs	739,431 shs
LENZ LENZ Therapeutics	$40.00 +0.4%	$32.84	$16.53 ▼ $41.70	$1.14B	0.42	299,254 shs	663,488 shs
RCUS Arcus Biosciences	$10.51 +0.3%	$9.22	$6.50 ▼ $18.98	$1.12B	0.89	1.02 million shs	726,948 shs
ZYME Zymeworks	$15.10 +4.9%	$13.17	$9.03 ▼ $17.70	$1.14B	1.26	530,202 shs	481,670 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	+0.86%	+1.15%	+2.92%	+21.72%	-7.59%
LENZ LENZ Therapeutics	+3.40%	-2.59%	+20.83%	+41.46%	+77.35%
RCUS Arcus Biosciences	+4.07%	+5.71%	+14.26%	+16.03%	-40.57%
ZYME Zymeworks	+0.49%	+0.63%	+0.49%	+24.70%	+29.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	1.793 of 5 stars	3.3	0.0	0.6	2.5	1.3
LENZ LENZ Therapeutics	1.3072 of 5 stars	2.6	1.0	3.8	0.8	0.0
RCUS Arcus Biosciences	2.2293 of 5 stars	3.4	3.0	2.0	1.7	0.0
ZYME Zymeworks	1.8677 of 5 stars	3.5	0.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	63.93% Upside
LENZ LENZ Therapeutics	3.17	Buy	$49.60	24.00% Upside
RCUS Arcus Biosciences	2.75	Moderate Buy	$21.14	101.19% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.43	41.91% Upside

Current Analyst Ratings Breakdown

Latest AVIR, RCUS, LENZ, and ZYME Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$19.00 ➝ $22.00
8/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$26.00 ➝ $25.00
7/31/2025	LENZ LENZ Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $49.00
7/31/2025	LENZ LENZ Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
7/28/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $48.00
7/3/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$13.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$4.59 per share	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.24 per share	N/A
RCUS Arcus Biosciences	$258M	4.34	N/A	N/A	$5.16 per share	2.04
ZYME Zymeworks	$122.87M	9.24	N/A	N/A	$6.63 per share	2.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$168.38M	-$1.61	N/A	N/A	N/A	N/A	-32.55%	-30.47%	11/6/2025 (Estimated)
LENZ LENZ Therapeutics	-$49.77M	-$1.90	N/A	N/A	N/A	N/A	-25.63%	-24.43%	11/5/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$3.17	N/A	N/A	N/A	-109.56%	-55.96%	-25.73%	11/5/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$0.97	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	10/30/2025 (Estimated)

Latest AVIR, RCUS, LENZ, and ZYME Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	AVIR Atea Pharmaceuticals	-$0.46	-$0.44	+$0.02	-$0.44	N/A	N/A
8/7/2025	N/A	ZYME Zymeworks	-$0.52	$0.03	+$0.55	N/A	$17.18 million	$48.73 million
8/6/2025	Q2 2025	RCUS Arcus Biosciences	-$1.14	-$1.1053	+$0.0347	N/A	$32.86 million	$160.00 million
7/30/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.58	-$0.53	+$0.05	-$0.53	$5.00 million	$5.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.17	19.17
LENZ LENZ Therapeutics	N/A	20.54	20.54
RCUS Arcus Biosciences	0.18	4.50	4.50
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
LENZ LENZ Therapeutics	54.32%
RCUS Arcus Biosciences	92.89%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
LENZ LENZ Therapeutics	6.90%
RCUS Arcus Biosciences	9.60%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	79.36 million	64.99 million	Optionable
LENZ LENZ Therapeutics	110	28.52 million	26.55 million	N/A
RCUS Arcus Biosciences	500	106.43 million	96.21 million	Optionable
ZYME Zymeworks	460	75.17 million	67.56 million	Optionable

AVIR, RCUS, LENZ, and ZYME Headlines

Recent News About These Companies

Zymeworks Reports Q2 Results and FDA Clearance

August 19 at 9:47 AM | theglobeandmail.com

Zymeworks Announces Participation in Upcoming Investor Conferences

August 19 at 6:00 AM | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Shares Purchased by Tejara Capital Ltd

August 17, 2025 | marketbeat.com

Zymeworks Earnings Call: Revenue Surge and Strategic Gains

August 13, 2025 | msn.com

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

August 12, 2025 | zacks.com

Citigroup Raises Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12, 2025 | marketbeat.com

Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12, 2025 | americanbankingnews.com

Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital

August 12, 2025 | marketbeat.com

Zymeworks Inc.: Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | finanznachrichten.de

Zymeworks Strengthens Leadership with New Board Appointments

August 11, 2025 | tipranks.com

Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors

August 11, 2025 | quiverquant.comQ

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | financialpost.comF

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from Analysts

August 11, 2025 | marketbeat.com

Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

August 10, 2025 | finance.yahoo.com

Zymeworks (NYSE:ZYME) Announces Earnings Results, Beats Expectations By $0.55 EPS

August 9, 2025 | marketbeat.com

Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression

August 8, 2025 | msn.com

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Zymeworks (ZYME) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR, RCUS, LENZ, and ZYME Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.66 +0.13 (+3.68%)

Closing price 04:00 PM Eastern

Extended Trading

$3.61 -0.05 (-1.37%)

As of 06:24 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

LENZ Therapeutics NASDAQ:LENZ

$40.00 +0.15 (+0.38%)

Closing price 04:00 PM Eastern

Extended Trading

$40.05 +0.05 (+0.12%)

As of 07:22 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Arcus Biosciences NYSE:RCUS

$10.51 +0.03 (+0.28%)

Closing price 03:59 PM Eastern

Extended Trading

$10.60 +0.09 (+0.87%)

As of 04:10 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Zymeworks NYSE:ZYME

$15.10 +0.71 (+4.93%)

Closing price 04:00 PM Eastern

Extended Trading

$15.11 +0.01 (+0.07%)

As of 06:18 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time